New York, NY, United States
New York, NY, United States

Time filter

Source Type

News Article | May 15, 2017
Site: globenewswire.com

MINNEAPOLIS, May 15, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), developer of the innovative STREAMWAY® waste fluid disposal system for medical applications, reports financial results for the three months ended March 31, 2017 and provides a business update. Highlights of the first quarter of 2017 and recent weeks include: “We are encouraged by our strengthened financial and operational performance during the first quarter, and by the momentum we are creating in broadening awareness of the STREAMWAY System, generating sales leads and increasing quotes,” said Dr. Carl Schwartz, Skyline’s chief executive officer.  “We owe this improvement in part to the hiring of four new sales representatives to start the year, and to a thoughtful and impactful sales and marketing strategy directed mainly to radiology suites.  We had a successful presence this past March at the Association for Medical Imaging Management Spring Conference.  This week we are exhibiting at the AHRA local meeting in San Antonio and at the CleanMed conference. “We are optimistic that our new sales and marketing staff, along with our focused marketing, will result in a growing number of customer leads.  The number of potential customers seeking live demonstrations of the STREAMWAY continues to grow and we are working to convert these inquiries into sales, a process that typically takes several months. “We also have initiated an education campaign related to our disposable products to ensure our customers adhere to proper maintenance and cleaning by replacing the filter after each use and employing our specialized cleaning fluids.  These efforts have started to generate a better recurring revenue source. “During the first quarter we were awarded a contract to sell the STREAMWAY System to customers of Vizient, the largest member-driven healthcare performance improvement general purchasing organization in the country. We continue to work with Vizient to reach its member organizations and are finalizing the marketing materials.” Dr. Schwartz continued, “In April we agreed to terminate our partnership and reseller agreement with GLG Pharma.  As the companies moved forward with their diligence, it became apparent that for the agreement to be successful Skyline would have to invest more money than originally contemplated.  Given that Skyline is not in a position to do so, and in order to facilitate GLG’s own future, the companies have jointly decided not to move forward.  We intend to review other potential distributors for Europe and the United Kingdom. “We continue to negotiate with select distributors in the U.S. while advancing our plan to engage 30 independent sales representatives to augment our five-person in-house sales organization.  We are optimistic that this sales approach will result in continued revenue increases throughout the remainder of the year,” Dr. Schwartz concluded. Revenue for the first quarter of 2017 was $175,166, compared with $96,505 for the first quarter of 2016.  Revenue was derived from the sale of STREAMWAY Systems and disposable products during both periods. Gross profit for the first quarter of 2017 was $138,174 or 78.9% of revenue, compared with $11,022 or 11.4% of revenue for the same period in 2016. Operating expenses for the first quarter of 2017 were $1,480,021, compared with $2,187,391 for the first quarter of 2016.  The decline was primarily due to reduced general and administrative expense to $1,132,073 for the first quarter of 2017 from $1,688,577 for the first quarter of 2016, reflecting lower legal fees and compensation. Net loss available to common shareholders for the first quarter of 2017 was $1,341,847 or $0.21 per share, compared with a net loss available to common shareholders for the first quarter of 2016 of $2,176,369 or $3.01 per share. Weighted average shares used in calculation of loss per common share was 6,450,967 shares in the 2017 quarter and 723,848 shares in the 2016 quarter. The Company had cash, cash equivalents and marketable securities of $4,780,393 as of March 31, 2017, compared with $2,148,419 as of December 31, 2016.  The Company raised gross proceeds of $4,295,812 in an underwritten public offering of stock and warrants during the first quarter of 2017. Skyline Medical management will host a conference call on May 16, 2017 beginning at 11:00 a.m. Eastern time to discuss first quarter financial results, expectations for 2017 and to answer questions. To access the conference call, please dial 844-666-7589 from within the U.S. or 443-961-0433 from outside the U.S. All listeners should provide passcode 20297561. Following the conclusion of the conference call, a telephone replay will be available through May 23, 2017 and can be accessed by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S.  All listeners should provide passcode 20297561. A live and archived webcast of the conference call will be available at www.skylinemedical.com. Skyline's revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.  As of March 31, 2017, Skyline Medical customers have installed 103 STREAMWAY Systems in 52 facilities across 20 states, and in Canada. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855. About Skyline Medical Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com. Forward-looking Statements Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.


News Article | May 15, 2017
Site: globenewswire.com

MINNEAPOLIS, May 15, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), developer of the innovative STREAMWAY® waste fluid disposal system for medical applications, reports financial results for the three months ended March 31, 2017 and provides a business update. Highlights of the first quarter of 2017 and recent weeks include: “We are encouraged by our strengthened financial and operational performance during the first quarter, and by the momentum we are creating in broadening awareness of the STREAMWAY System, generating sales leads and increasing quotes,” said Dr. Carl Schwartz, Skyline’s chief executive officer.  “We owe this improvement in part to the hiring of four new sales representatives to start the year, and to a thoughtful and impactful sales and marketing strategy directed mainly to radiology suites.  We had a successful presence this past March at the Association for Medical Imaging Management Spring Conference.  This week we are exhibiting at the AHRA local meeting in San Antonio and at the CleanMed conference. “We are optimistic that our new sales and marketing staff, along with our focused marketing, will result in a growing number of customer leads.  The number of potential customers seeking live demonstrations of the STREAMWAY continues to grow and we are working to convert these inquiries into sales, a process that typically takes several months. “We also have initiated an education campaign related to our disposable products to ensure our customers adhere to proper maintenance and cleaning by replacing the filter after each use and employing our specialized cleaning fluids.  These efforts have started to generate a better recurring revenue source. “During the first quarter we were awarded a contract to sell the STREAMWAY System to customers of Vizient, the largest member-driven healthcare performance improvement general purchasing organization in the country. We continue to work with Vizient to reach its member organizations and are finalizing the marketing materials.” Dr. Schwartz continued, “In April we agreed to terminate our partnership and reseller agreement with GLG Pharma.  As the companies moved forward with their diligence, it became apparent that for the agreement to be successful Skyline would have to invest more money than originally contemplated.  Given that Skyline is not in a position to do so, and in order to facilitate GLG’s own future, the companies have jointly decided not to move forward.  We intend to review other potential distributors for Europe and the United Kingdom. “We continue to negotiate with select distributors in the U.S. while advancing our plan to engage 30 independent sales representatives to augment our five-person in-house sales organization.  We are optimistic that this sales approach will result in continued revenue increases throughout the remainder of the year,” Dr. Schwartz concluded. Revenue for the first quarter of 2017 was $175,166, compared with $96,505 for the first quarter of 2016.  Revenue was derived from the sale of STREAMWAY Systems and disposable products during both periods. Gross profit for the first quarter of 2017 was $138,174 or 78.9% of revenue, compared with $11,022 or 11.4% of revenue for the same period in 2016. Operating expenses for the first quarter of 2017 were $1,480,021, compared with $2,187,391 for the first quarter of 2016.  The decline was primarily due to reduced general and administrative expense to $1,132,073 for the first quarter of 2017 from $1,688,577 for the first quarter of 2016, reflecting lower legal fees and compensation. Net loss available to common shareholders for the first quarter of 2017 was $1,341,847 or $0.21 per share, compared with a net loss available to common shareholders for the first quarter of 2016 of $2,176,369 or $3.01 per share. Weighted average shares used in calculation of loss per common share was 6,450,967 shares in the 2017 quarter and 723,848 shares in the 2016 quarter. The Company had cash, cash equivalents and marketable securities of $4,780,393 as of March 31, 2017, compared with $2,148,419 as of December 31, 2016.  The Company raised gross proceeds of $4,295,812 in an underwritten public offering of stock and warrants during the first quarter of 2017. Skyline Medical management will host a conference call on May 16, 2017 beginning at 11:00 a.m. Eastern time to discuss first quarter financial results, expectations for 2017 and to answer questions. To access the conference call, please dial 844-666-7589 from within the U.S. or 443-961-0433 from outside the U.S. All listeners should provide passcode 20297561. Following the conclusion of the conference call, a telephone replay will be available through May 23, 2017 and can be accessed by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S.  All listeners should provide passcode 20297561. A live and archived webcast of the conference call will be available at www.skylinemedical.com. Skyline's revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.  As of March 31, 2017, Skyline Medical customers have installed 103 STREAMWAY Systems in 52 facilities across 20 states, and in Canada. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855. About Skyline Medical Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com. Forward-looking Statements Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.


News Article | May 15, 2017
Site: globenewswire.com

MINNEAPOLIS, May 15, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), developer of the innovative STREAMWAY® waste fluid disposal system for medical applications, reports financial results for the three months ended March 31, 2017 and provides a business update. Highlights of the first quarter of 2017 and recent weeks include: “We are encouraged by our strengthened financial and operational performance during the first quarter, and by the momentum we are creating in broadening awareness of the STREAMWAY System, generating sales leads and increasing quotes,” said Dr. Carl Schwartz, Skyline’s chief executive officer.  “We owe this improvement in part to the hiring of four new sales representatives to start the year, and to a thoughtful and impactful sales and marketing strategy directed mainly to radiology suites.  We had a successful presence this past March at the Association for Medical Imaging Management Spring Conference.  This week we are exhibiting at the AHRA local meeting in San Antonio and at the CleanMed conference. “We are optimistic that our new sales and marketing staff, along with our focused marketing, will result in a growing number of customer leads.  The number of potential customers seeking live demonstrations of the STREAMWAY continues to grow and we are working to convert these inquiries into sales, a process that typically takes several months. “We also have initiated an education campaign related to our disposable products to ensure our customers adhere to proper maintenance and cleaning by replacing the filter after each use and employing our specialized cleaning fluids.  These efforts have started to generate a better recurring revenue source. “During the first quarter we were awarded a contract to sell the STREAMWAY System to customers of Vizient, the largest member-driven healthcare performance improvement general purchasing organization in the country. We continue to work with Vizient to reach its member organizations and are finalizing the marketing materials.” Dr. Schwartz continued, “In April we agreed to terminate our partnership and reseller agreement with GLG Pharma.  As the companies moved forward with their diligence, it became apparent that for the agreement to be successful Skyline would have to invest more money than originally contemplated.  Given that Skyline is not in a position to do so, and in order to facilitate GLG’s own future, the companies have jointly decided not to move forward.  We intend to review other potential distributors for Europe and the United Kingdom. “We continue to negotiate with select distributors in the U.S. while advancing our plan to engage 30 independent sales representatives to augment our five-person in-house sales organization.  We are optimistic that this sales approach will result in continued revenue increases throughout the remainder of the year,” Dr. Schwartz concluded. Revenue for the first quarter of 2017 was $175,166, compared with $96,505 for the first quarter of 2016.  Revenue was derived from the sale of STREAMWAY Systems and disposable products during both periods. Gross profit for the first quarter of 2017 was $138,174 or 78.9% of revenue, compared with $11,022 or 11.4% of revenue for the same period in 2016. Operating expenses for the first quarter of 2017 were $1,480,021, compared with $2,187,391 for the first quarter of 2016.  The decline was primarily due to reduced general and administrative expense to $1,132,073 for the first quarter of 2017 from $1,688,577 for the first quarter of 2016, reflecting lower legal fees and compensation. Net loss available to common shareholders for the first quarter of 2017 was $1,341,847 or $0.21 per share, compared with a net loss available to common shareholders for the first quarter of 2016 of $2,176,369 or $3.01 per share. Weighted average shares used in calculation of loss per common share was 6,450,967 shares in the 2017 quarter and 723,848 shares in the 2016 quarter. The Company had cash, cash equivalents and marketable securities of $4,780,393 as of March 31, 2017, compared with $2,148,419 as of December 31, 2016.  The Company raised gross proceeds of $4,295,812 in an underwritten public offering of stock and warrants during the first quarter of 2017. Skyline Medical management will host a conference call on May 16, 2017 beginning at 11:00 a.m. Eastern time to discuss first quarter financial results, expectations for 2017 and to answer questions. To access the conference call, please dial 844-666-7589 from within the U.S. or 443-961-0433 from outside the U.S. All listeners should provide passcode 20297561. Following the conclusion of the conference call, a telephone replay will be available through May 23, 2017 and can be accessed by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S.  All listeners should provide passcode 20297561. A live and archived webcast of the conference call will be available at www.skylinemedical.com. Skyline's revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids.  As of March 31, 2017, Skyline Medical customers have installed 103 STREAMWAY Systems in 52 facilities across 20 states, and in Canada. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.  For a demonstration please visit www.skylinemedical.com or call 855-785-8855. About Skyline Medical Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com. Forward-looking Statements Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.


News Article | May 24, 2017
Site: www.prnewswire.com

Browse 62 market data tables and 59 figures spread through 141 pages and in-depth TOC on "Stevia Market - Global Forecasts to 2022" Early buyers will receive 10% customization on this report. Stevia has its own unique taste profile and sweetness intensity which is approximately 200 to 350 times greater than regular sugar. Many food & beverage companies use stevia to create products with enhanced taste and fewer total calories. With heavy investment in R&D, new applications such as zero-calorie products and flavor enhancers are emerging rapidly. Stevia offers several advantages such as sugar preplacement, reduction in calories, sweetness, texture, color, and flavor enhancement. Hence, stevia will be viewed as a business opportunity in the next five years. As a result, many multinational players have entered into the production of varied types of stevia. Powdered extracts segment is projected to be the fastest-growing in the Stevia Market Among the extract types of stevia which include whole leaf, powdered, and liquid the powdered extracts segment is expected to grow at the highest CAGR with increasing applications in the convenience foods and beverage industries. Stevia powdered extracts vary in terms of taste, sweetness, and cost of various white stevia powders; these parameters are more likely to be dependent on the degree of refinement and the quality of the stevia plant used. It is also a cost-effective option which further satisfies the growing demand for sugar replacement products from consumers as well. Beverages: The most popular application for stevia globally in 2016 The beverages segment accounted for the largest share in the Stevia Market in terms of both, value as well as volume in 2016. Stevia is the most preferred option for beverage manufacturers as the bulking properties provided by sugar are not required. Stevia is one of the most common natural sweeteners used for zero- or low-calorie beverages. It is mostly used in beverages such as diet carbonated drinks, flavored water, soft drinks, fruit juices, ready-to-drink beverages, and sports & energy drinks. Increase in consumption of convenience foods in developing countries to boost the Stevia Market Developing economies in the Asia-Pacific region are prospering in terms of increasing GDP with the working population on the rise. With the rise in population and improved purchasing power of developing countries such as China and India, the market for stevia is expected to show double-digit growth in the future. Factors such as changes in eating habits of consumers, increase in urbanization, and rise in the consumption patterns of stevia products have driven growth in the market in the Asia-Pacific region. This report includes a study of marketing and development strategies, along with the product portfolios of leading companies. It includes the profiles of leading companies such as Cargill (U.S.), Ingredion Inc. (U.S.), Tate & Lyle PLC (U.K.), PureCircle Ltd. (Malaysia), and GLG Life Tech Corporation (Canada). The report covers the stevia whole leaf, powdered, and liquid extracts segments in terms of value and volume. In terms of insights, this research report has focused on various levels of analysis industry analysis, market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging & high-growth segments of the global Stevia Market, high-growth regions, countries, and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. Industrial Sugar Market by Type (White, Brown & Liquid), Form (Granulated, Powdered & Syrup), Application (Dairy, Bakery, Confectionery, Beverage, Canned & Frozen Foods, Other Food Items & Pharmaceuticals), Source (Cane Sugar, Beet Suger), and Region - Global Forecast to 2022 Sugar Substitutes Market by Type (HIS, LIS, HFS), Composition (Stevia, Aspartame, Cyclamate, Sucralose, Saccharin, AceK, D-Tagarose, Sorbitol, Maltitol, Xylitol, Mannitol), Application (Beverages, Food, Health & Personal Care), & by Region - Forecast to 2020 MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Visit Our Blog @ http://www.marketsandmarketsblog.com/market-reports/food-and-beverage Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 24, 2017
Site: www.prnewswire.co.uk

Browse 62 market data tables and 59 figures spread through 141 pages and in-depth TOC on "Stevia Market - Global Forecasts to 2022" Early buyers will receive 10% customization on this report. Stevia has its own unique taste profile and sweetness intensity which is approximately 200 to 350 times greater than regular sugar. Many food & beverage companies use stevia to create products with enhanced taste and fewer total calories. With heavy investment in R&D, new applications such as zero-calorie products and flavor enhancers are emerging rapidly. Stevia offers several advantages such as sugar preplacement, reduction in calories, sweetness, texture, color, and flavor enhancement. Hence, stevia will be viewed as a business opportunity in the next five years. As a result, many multinational players have entered into the production of varied types of stevia. Powdered extracts segment is projected to be the fastest-growing in the Stevia Market Among the extract types of stevia which include whole leaf, powdered, and liquid the powdered extracts segment is expected to grow at the highest CAGR with increasing applications in the convenience foods and beverage industries. Stevia powdered extracts vary in terms of taste, sweetness, and cost of various white stevia powders; these parameters are more likely to be dependent on the degree of refinement and the quality of the stevia plant used. It is also a cost-effective option which further satisfies the growing demand for sugar replacement products from consumers as well. Beverages: The most popular application for stevia globally in 2016 The beverages segment accounted for the largest share in the Stevia Market in terms of both, value as well as volume in 2016. Stevia is the most preferred option for beverage manufacturers as the bulking properties provided by sugar are not required. Stevia is one of the most common natural sweeteners used for zero- or low-calorie beverages. It is mostly used in beverages such as diet carbonated drinks, flavored water, soft drinks, fruit juices, ready-to-drink beverages, and sports & energy drinks. Increase in consumption of convenience foods in developing countries to boost the Stevia Market Developing economies in the Asia-Pacific region are prospering in terms of increasing GDP with the working population on the rise. With the rise in population and improved purchasing power of developing countries such as China and India, the market for stevia is expected to show double-digit growth in the future. Factors such as changes in eating habits of consumers, increase in urbanization, and rise in the consumption patterns of stevia products have driven growth in the market in the Asia-Pacific region. This report includes a study of marketing and development strategies, along with the product portfolios of leading companies. It includes the profiles of leading companies such as Cargill (U.S.), Ingredion Inc. (U.S.), Tate & Lyle PLC (U.K.), PureCircle Ltd. (Malaysia), and GLG Life Tech Corporation (Canada). The report covers the stevia whole leaf, powdered, and liquid extracts segments in terms of value and volume. In terms of insights, this research report has focused on various levels of analysis industry analysis, market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging & high-growth segments of the global Stevia Market, high-growth regions, countries, and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. Industrial Sugar Market by Type (White, Brown & Liquid), Form (Granulated, Powdered & Syrup), Application (Dairy, Bakery, Confectionery, Beverage, Canned & Frozen Foods, Other Food Items & Pharmaceuticals), Source (Cane Sugar, Beet Suger), and Region - Global Forecast to 2022 Sugar Substitutes Market by Type (HIS, LIS, HFS), Composition (Stevia, Aspartame, Cyclamate, Sucralose, Saccharin, AceK, D-Tagarose, Sorbitol, Maltitol, Xylitol, Mannitol), Application (Beverages, Food, Health & Personal Care), & by Region - Forecast to 2020 MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Visit Our Blog @ http://www.marketsandmarketsblog.com/market-reports/food-and-beverage Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 4, 2017
Site: www.prnewswire.com

LONDON, May 4, 2017 /PRNewswire/ -- About Tabletop and Sachet Sweeteners The application market of sweeteners has a larger contribution to the overall revenue compared with the direct consumption of sweeteners by end-users. The food and beverage industry is focusing on replacing sugar with sugar substitutes. This is creating a cost-cutting advantage for production. This is because, when compared with sugar, these substitutes are required in lesser quantities for the same sweet taste. This has accelerated the demand for sweeteners. Low-intensity sweeteners (LIS) can be consumed by people with diabetes. The lower calorie value of LIS controls insulin secretion, which in turn controls the blood sugar level. The demand for LIS is increasing in North America and is driving the sales of sweeteners. Download the full report: https://www.reportbuyer.com/product/4877216/ Technavio's analysts forecast the global tabletop and sachet sweeteners market to grow at a CAGR of 8.66% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global tabletop and sachet sweeteners market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography: • APAC • Europe • North America • ROW Technavio's report, Global Tabletop and Sachet Sweeteners Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors • AJINOMOTO • Cargill • PureCircle • ROQUETTE • Tate & Lyle Other prominent vendors • Cumberland Packing • DOMINO FOODS • GLG Leading Life Technologies • Heartland Food Products Group • Hermesetas • Merisant • NUTRASTEVIA • Stevia First • SteviaOne • Sunwin Stevia International • Wholesome! Market driver • High awareness about sweeteners in developed countries. • For a full, detailed list, view our report Market challenge • Patent expirations and high R&D investments. • For a full, detailed list, view our report Market trend • Natural sweeteners witnessing increased demand. • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2021 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report. Methodology Download the full report: https://www.reportbuyer.com/product/4877216/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com   Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-tabletop-and-sachet-sweeteners-market-2017-2021-300451727.html


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Stevia Market - Growth, Trends and Forecasts (2017 - 2022)" report to their offering. The global Stevia market is expected to grow at a CAGR of more than 8% during the period 2017-2022 Manufacturers are increasingly exploring alternative sweeteners, which will enable a reduction in calorific content without sacrificing the taste. Increasing awareness of the health benefits of low-calorie consumable products is a major catalyst to the market growth. Companies like Cargill, PureCirle, GLG Life Tech are major shareholders in the marketplace. As consumers have moved away from sugar and towards natural ingredients, demand for plant-based sweeteners like Stevia has increased, which has established itself as a healthy alternative to sugar. New product development, improved taste, and versatility, along with high levels of marketing support are likely to increase the demand for stevia-based products and boost the market growth. The growing awareness about the health benefits associated with stevia is leading to the extensive use of these products in the food and beverage sector. As the number of obese and diabetic people are on the rise, Stevia is the best sugar alternative due to its zero-calorie property. As a sweetener, it has always been in the news due to various regulatory constraints, which is a major threat to the stevia market. Another threat to the market is the availability of other low-calorie sweeteners. The growing sports nutrition product and health drink market would further boost this industry's growth. The global stevia market is segmented by type into powder, liquid and leaf. Stevia is widely used in the powdered form across the globe; hence, it holds the largest segment in the market. The market is segmented by application into bakery, dairy food, beverages, dietary supplements, confectionery and others. Stevia is widely used in a variety of food products such as confectionery, desserts, baked foods, snack foods, and jellies, as it can be easily incorporated and imparts sweetness to the product, with very low-calorie. Some of the major players in the market include For more information about this report visit http://www.researchandmarkets.com/research/bdmr4p/global_stevia


— Global Stevia Rebaudiana Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are PureCircle, GLG Life Tech Corp, Julong High-tech, Biolotus Technology, Haotian Pharm, Cargill-Layn, Haigen Stevia, Sunwin Stevia, Merisant, Jining Aoxing Stevia Products, Tate & Lyle, Shandong Shengxiangyuan, Daepyung, GL Stevia, Morita Kagaku Kogyo, Ingredion, Stevia Sweetener, Wagott Pharmaceutical and Wisdom Natural Brands in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • Reb-A Series • STV Series • Glucosyl Stevia • Others Split by applications, this report focuses on sales, market share and growth rate of Stevia Rebaudiana in each application, can be divided into • Food • Beverage • Pharmaceutical Industry • Daily Chemical Industry • Others Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/477089 1 Stevia Rebaudiana Market Overview 2 Global Stevia Rebaudiana Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Stevia Rebaudiana Manufacturers Profiles/Analysis 5 North America Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Stevia Rebaudiana Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Stevia Rebaudiana Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Stevia Rebaudiana Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/477089 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-stevia-rebaudiana-market-report%20


News Article | May 4, 2017
Site: www.PR.com

Receive press releases from Langson Energy Inc.: By Email This study will evaluate the technical, commercial, financial, and environmental viability of utilizing Langson Energy’s 5 MW Total Flow Generator to make more efficient use of the geothermal resource at Olkaria. Upon the successful results of the study, KenGen and LEI will have the opportunity to install a number of additional units in the more than 275 wells which will optimize power plant efficiency and greatly impact the electric footprint in the country. Langson Energy‘s Senior Engineer, Dr. Ron DiPippo, will be the Geothermal Expert on the project working with a team of 10 other experts. As Author of 4 major books including, Geothermal Power Plants: Principles, Applications and Case Studies, Dr. DiPippo is the foremost world authority and consultant on Geothermal Power Plants. In addition to Dr. DiPippo’s experience with the Olkaria Geothermal Power Plant in Kenya, he has worked in many geothermally active US states and countries around the world. Dr. DiPippo states, “The advantages of a thermodynamically equivalent Total Flow Generator will lie in its simplicity, lower capital cost, ease and rapidity of installation, reliable operation, lower cost of electricity, and ability to operate on lower-temperature reservoirs, compared to either flash-steam or binary systems.” About Langson Energy Incorporated Langson Energy has developed an award-winning, exceptionally efficient power conversion system, the Total Flow GeneratorTM, which converts pressure to power. These unique direct-expansion, positive displacement devices are unaffected by variations in pressures and flows and solve the challenges of expansion turbines. They are capable of directly utilizing the pressure in natural gas, wet steam, dry steam, geothermal fluids and many other waste streams and waste heat. The Gas Pressure Letdown GeneratorTM (GLG) can produce base load green power from pressure currently being wasted by regulators and Pressure Reduction Valves (PRVs) anywhere. The Steam Machine can utilize saturated steam generated from any source of waste heat and even geothermal brine. Both machines provide significant economic and performance advantages over traditional and nontraditional waste energy capture devices to provide on-site or distributed low-cost clean energy. Carson City, NV, May 04, 2017 --( PR.com )-- Langson Energy, Inc. (LEI), a USA energy equipment manufacturer, was selected by Kenya Electricity Generating Limited (KenGen), producer of around 80% of the power consumed in Kenya, to conduct a green technology feasibility study for their Olkaria Geothermal Power Plant. KenGen has been searching for a specialized genset that can be installed upstream as a topping unit capable of accepting high pressure geothermal wellhead pressures to capture the waste energy and generate additional clean electricity. Representatives from KenGen and the United States Trade and Development Agency (USTDA), which will be partially funding the study, were in Nairobi, Kenya for this historic grant signing on April 27, 2017. “USTDA is pleased to facilitate new business partnerships between U.S. and Kenyan companies that can spur long-term, sustainable economic growth,” said Sub-Saharan Africa Regional Director Lida Fitts. “The adoption of innovative and cost-effective U.S. technology can help Kenya to meet its energy development goals.”This study will evaluate the technical, commercial, financial, and environmental viability of utilizing Langson Energy’s 5 MW Total Flow Generator to make more efficient use of the geothermal resource at Olkaria. Upon the successful results of the study, KenGen and LEI will have the opportunity to install a number of additional units in the more than 275 wells which will optimize power plant efficiency and greatly impact the electric footprint in the country.Langson Energy‘s Senior Engineer, Dr. Ron DiPippo, will be the Geothermal Expert on the project working with a team of 10 other experts. As Author of 4 major books including, Geothermal Power Plants: Principles, Applications and Case Studies, Dr. DiPippo is the foremost world authority and consultant on Geothermal Power Plants. In addition to Dr. DiPippo’s experience with the Olkaria Geothermal Power Plant in Kenya, he has worked in many geothermally active US states and countries around the world. Dr. DiPippo states, “The advantages of a thermodynamically equivalent Total Flow Generator will lie in its simplicity, lower capital cost, ease and rapidity of installation, reliable operation, lower cost of electricity, and ability to operate on lower-temperature reservoirs, compared to either flash-steam or binary systems.”About Langson Energy IncorporatedLangson Energy has developed an award-winning, exceptionally efficient power conversion system, the Total Flow GeneratorTM, which converts pressure to power. These unique direct-expansion, positive displacement devices are unaffected by variations in pressures and flows and solve the challenges of expansion turbines. They are capable of directly utilizing the pressure in natural gas, wet steam, dry steam, geothermal fluids and many other waste streams and waste heat. The Gas Pressure Letdown GeneratorTM (GLG) can produce base load green power from pressure currently being wasted by regulators and Pressure Reduction Valves (PRVs) anywhere. The Steam Machine can utilize saturated steam generated from any source of waste heat and even geothermal brine. Both machines provide significant economic and performance advantages over traditional and nontraditional waste energy capture devices to provide on-site or distributed low-cost clean energy. Click here to view the list of recent Press Releases from Langson Energy Inc.


The North America Stevia market is expected to grow at a CAGR of 9.8 % during the period 2017-2022 Manufacturers are increasingly exploring alternative sweeteners which will enable a reduction in calorific content, without sacrificing taste. Increasing awareness of the health benefits of low calorie consumable products is a major catalyst. Companies like Cargill, PureCirle, GLG Life Tech are the major shareholders in the marketplace. Shift in consumer preference towards adopting food & beverages based on natural ingredient are likely to favor market growth. FDA (United States Food and Drug Administration) approval and attributing GRAS (Generally Recognized as Safe) status to steviol glycosides with reduced RebA in 2010 is likely to positively influence on stevia demand. North America is the largest market for confectionaries and baked goods, thus driving the demand for Stevia. Increasing demand for healthy and natural eating products has prompted the need for alternative sweeteners like Stevia. As the number of obese and diabetic people is on the rise, Stevia is the best sugar alternative as it has zero calories. Major threat is the availability of the other low calorie sweeteners. The growing sports nutrition product and health drink market would provide a further boost to the industry's growth. Food & beverage, healthcare and personal care industries create opportunities of a prospering market for Stevia. The market is highly fragmented because of the presence of numerous small and large vendors. Most of the companies engage in aggressive promotion of stevia-based products in order to improve product positioning and visibility. The demand for low-calorie beverages such as juices, flavored water, sports drinks, energy drinks, and soft drinks is driving vendors to manufacture products that are not only unique and attractive but also healthy. This is leading to a tough competition in the market with vendors competing on the basis of price, quality, product differentiation, distribution, and promotion. Some of the major players in the market include: - Cargill Inc - Sweetleaf - Stevia First Corporation - Tate & Lyle - Hermes Sweetners Ltd 4. Market Dynamics 4.1 Drivers 4.1.1 Increased awareness on the health benefits of low-calorie consumable products 4.1.2 Rising demand for plant-based sweeteners and natural ingredients 4.1.3 Largest market for Confectionary and Baked goods 4.2 Restraints 4.2.1 Stringent Regulatory Enviornment 4.2.2 Availability of Other low Calorie Sweetners 4.3 Opportunities 4.3.1 Stevia Incorporation in Sports Nutrition product 4.4 Porter's Five Forces Analysis 6. Competitive Landscape 6.1 Strategy adopted by Key players 6.2 Most active companies in the past five years 6.3 Market Share Analysis For more information about this report visit http://www.researchandmarkets.com/research/kdx55t/north_america To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---north-america-stevia-market-2017-2022-leading-players-are-cargill-purecirle-glg-life-tech-300444189.html

Loading GLG Inc collaborators
Loading GLG Inc collaborators